Hear about the management of extramedullary disease in #MultipleMyeloma by watching our recent interview from #COMy2025 with the wonderful Meral Beksac (@beksac.bsky.social):
👉 buff.ly/76y25XF 👈
#MMSM #Myeloma #HemOnc #BloodSky #MedSky #HemeSky #Hematology
Happy to share my pride for having received the 2024 service award of “Scientific and Research Council of Turkey”
Patients on myeloma treatment can sometimes be at risk for certain infections, like the flu. Data from a study at #ASH24 shows the benefit of multiple influenza vaccine doses to better protect patients during the flu season.
Results from the phase 3 CEPHEUS clinical trial show the promise of DVRd treatment as a standard frontline therapy for patients without stem cell transplant: 1) quicker time to reaching MRD negativity and 2) longer time staying MRD negative. #ASH24
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Thanks 🙏appreciate
Our earlier published EBMT early relapse score is validated in an external database of five registries Worldwide within WBMT a predictive approach to functional high risk ash.confex.com/ash/2024/web...
I will be happy to be included as well Meral Beksac Ankara Turkey
